Table 4.

HR (95% CI) and P values for all-cause, cardiovascular, and noncardiovascular mortality in the combined cohort

NECOSAD and Swedish	CCR5 ins/ins and hsCRP < 10 mg/L (n = 392)	CCR5 ins/ins and hsCRP > 10 mg/L (n = 187)	CCR5Δ32 and hsCRP < 10 mg/L (n = 89)	CCR5Δ32 and hsCRP > 10 mg/L (n = 47)
All-cause mortality
Crude HR	1	2.46 (1.87 to 3.25)	1.16 (0.77 to 1.76)	1.42 (0.86 to 2.34)
P		<0.01	0.49	0.17
Adjusted HR	1	1.73 (1.31 to 2.30)	1.09 (0.72 to 1.66)	1.23 (0.74 to 2.02)
P		<0.01	0.69	0.42
Cardiovascular mortality
Crude HR	1	2.48 (1.72 to 3.56)	1.14 (0.66 to 1.98)	1.36 (0.70 to 2.65)
P		<0.01	0.63	0.37
Adjusted HR	1	1.76 (1.21 to 2.54)	1.16 (0.67 to 2.03)	1.15 (0.59 to 2.25)
P		<0.01	0.59	0.68
Noncardiovascular mortality
Crude HR	1	2.45 (1.60 to 3.74)	1.18 (0.63 to 2.23)	1.50 (0.71 to 3.18)
P		<0.01	0.61	0.29
Adjusted HR	1	1.70 (1.10 to 2.62)	1.03 (0.54 to 1.95)	1.31 (0.62 to 2.79)
P		0.02	0.94	0.48

Adjusted for gender, age at inclusion, cardiovascular disease, diabetes, and dialysis modality.